The global Angiotensin II receptor blockers Market was valued at USD 7.87 Billion in 2020 and is projected to reach USD 10.34 Billion by 2028, with a compound annual growth rate (CAGR) of 3.51%. These drugs block the renin-angiotensin system, leading to a decrease in blood pressure and inhibition of various angiotensin-related pathological processes, such as vasoconstriction, apoptosis, inflammation, fibrosis, and coagulation. As a result, ARB drugs are commonly used to treat conditions such as coronary heart disease, heart failure, diabetic nephropathy, and hypertension. Moreover, ARB drugs selectively block the angiotensin type-1 receptor without affecting the type-2 receptor. This selective action offers additional benefits in terms of improving endothelial dysfunction, preventing vascular remodeling, ensuring cardiac safety, and providing renal protection. These drugs also have a positive impact on the progression of diabetic nephropathy and the development of proteinuria in patients with type 2 diabetes. Importantly, these effects are independent of their blood pressure-lowering properties. Get a sample of the report @ Companies considered and profiled in this market study AstraZeneca, Daichii Sankyo, Novartis, Abbvie, Lupin, Takeda, and Zydus Cadila. To know more about the report @ The Angiotensin II receptor blockers (ARB) market is driven by several factors. Firstly, the rising prevalence of cardiovascular diseases such as coronary heart disease and heart failure has increased the demand for ARB drugs as they are widely used in the treatment of these conditions. Additionally, the growing incidence of hypertension and its associated complications has further fueled the market growth. Furthermore, the increasing awareness among healthcare professionals and patients about the benefits of ARB drugs, such as their ability to reduce blood pressure and inhibit angiotensin-related pathophysiological actions, has contributed to the market expansion. The efficacy and safety of ARB drugs, along with their potential for providing additional cardiovascular and renal benefits, have also played a role in driving their adoption. On the other hand, there are certain restraints that can affect the Angiotensin II receptor blockers market. Patent expirations of major ARB drugs have led to the entry of generic versions, resulting in price erosion and impacting the market value. This has led to increased competition among manufacturers and reduced profit margins. Additionally, stringent regulatory requirements and the need for extensive clinical trials for drug approvals pose challenges to market growth. The high cost associated with research and development, as well as the potential adverse effects and drug interactions of ARB drugs, can also limit their adoption. Moreover, the availability of alternative treatment options such as angiotensin-converting enzyme (ACE) inhibitors and calcium channel blockers may influence the prescribing decisions of healthcare professionals and affect the market demand for ARB drugs. Overall, while there are driving factors such as the increasing prevalence of cardiovascular diseases and growing awareness about the benefits of ARB drugs, there are also restraints including generic competition, regulatory challenges, and the availability of alternative treatments that can impact the Angiotensin II receptor blockers market. Request a customization of the report @ About Us: Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Contact Us: John W Head of Business Development Direct Line: +1-212-710-1370 E-mail: Reports and Data | Web: Check our upcoming research reports @ Visit our blog for more industry updates @